Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027,... Read More

HENDERSON, Nev. / Feb 24, 2025 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will... Read More

TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. TibuSURE launches with the initiation of its first clinical site. HENDERSON, Nev. / Dec 23, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the... Read More

HENDERSON, Nev. / Nov 25, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and... Read More

HENDERSON, Nev. / Nov 14, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a... Read More

Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 HENDERSON, Nev. / Nov 07, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical... Read More

HENDERSON, Nev. / Oct 30, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November. Conference Details: Event: Guggenheim Inaugural Healthcare Innovation Conference... Read More

HENDERSON, Nev. / Sep 03, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present at three upcoming investor conferences in September. Conference Details: Event: H.C. Wainwright 26 th Annual Global Investment... Read More

Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of... Read More

HENDERSON, Nev. / Aug 12, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has completed its previously announced exchange offer (the “Exchange Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i) public... Read More

HENDERSON, Nev. / Aug 09, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the expiration and results of its previously announced exchange offer (the “Exchange Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i)... Read More

HENDERSON, Nev. / Jul 12, 2024 / Business Wire / Zura Bio Limited (NASDAQ: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i) public warrants that were issued in... Read More

Tibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren’s syndrome Preclinical data demonstrating the potential of dual inhibition of IL-17A and BAFF in a rheumatoid arthritis animal model support clinical development HENDERSON, Nev. / Jun 14, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel... Read More

HENDERSON, Nev. / Jun 06, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the formation of a Scientific Advisory Board (SAB) with leading experts from rheumatology, dermatology, and immunology. The five distinguished founding members of the SAB are Johann Gudjonsson, M.D,... Read More

Novel, dual-pathway antibody targeting IL-17A and BAFF is expected to enter Phase 2 development in systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025 HENDERSON, Nev. / Jun 03, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its... Read More

HENDERSON, Nev. / May 29, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June. Conference Details: Event: Jefferies Global Healthcare Conference Details: Michael Howell, Ph.D., Chief... Read More

Ended Q1 2024 with $89.8 million in cash and closed oversubscribed $112.5 million private placement in April 2024 from new and existing leading life sciences institutional investors Appointed Robert Lisicki as CEO and Kiran Nistala, M.B.B.S., Ph.D. as CMO On track to initiate Phase 2 studies evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025... Read More

Financing includes new and existing leading life sciences institutional investors Strengthened balance sheet expected to fund operations through 2027 HENDERSON, Nev. / Apr 18, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has entered into... Read More

Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director Recognized as inspirational industry leader with exceptional R&D, commercial and global executive experience Outstanding product development and commercialization track record across a number of leading I&I therapies spanning nearly 30 years... Read More

Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO, Robert Lisicki, underscores Zura Bio’s commitment to building leading immunology company as we prioritize excellence in strategic... Read More

HENDERSON, Nev. / Mar 04, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate in three conferences in March. Conference Details: Event: Leerink Global Biopharma Conference Details: Robert Lisicki, President... Read More

HENDERSON, Nev. / Feb 02, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate at several upcoming conferences in February. Conference Details: Event: Oppenheimer 2024 Winter CEO and Investor Summit Details:... Read More

Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio’s Clinical Development programs Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 HENDERSON, Nev. / Jan 08, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel... Read More

HENDERSON, Nev. / Jan 03, 2024 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will present at two upcoming conferences in January. Conference Details: Event: 2024 Dermatology Summit Date: Sunday, January 7, 2024 Time: 4:00... Read More

HENDERSON, Nev. / Dec 04, 2023 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand. The abstracts highlight Zura Bio’s informative research for... Read More

HENDERSON, Nev. / Nov 14, 2023 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the Board of Directors appointed Arnout Ploos van Amstel as Non-Executive Independent Director by way of co-optation. Mr. Ploos van Amstel replaces Dr. Garry Neil who will continue to support... Read More

Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 HENDERSON, Nev. / Nov 13, 2023 / Business Wire / Zura Bio Limited (Nasdaq: ZURA)... Read More

Benaroya Research Institute to further characterize role of IL-7Rα in TSLP and IL-7 signaling pathways Agreement underscores Zura Bio’s commitment to advancing science in immune-mediated disorders HENDERSON, Nev. / Sep 12, 2023 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, and... Read More

Focused on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist for systemic sclerosis and hidradenitis suppurativa Experienced team building the next immunology leader Cash and cash equivalents of $113 million support development and operations through 2026 HENDERSON, Nev. / Aug 14, 2023 / Business Wire / Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a multi-asset... Read More

SAN DIEGO / Jun 23, 2023 / Business Wire / Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced it will be added to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June... Read More

Tibulizumab (ZB-106) was licensed from Eli Lilly and Company on April 26, 2023 Total cash and cash equivalents of approximately $120 million is expected to fund planned clinical and operating activities through 2026 SAN DIEGO / Jun 06, 2023 / Business Wire / Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory... Read More